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Abstract 
 
The development of pharmacological magnetic resonance imaging (phMRI) has presented the 
opportunity for investigation of the neurophysiological effects of drugs in vivo. Psilocin, a 
hallucinogen metabolised from psilocybin, was recently reported to evoke brain region-specific, 
phMRI signal changes in humans. The present study investigated the effects of psilocin in a rat 
model using phMRI and then probed the relationship between neuronal and haemodynamic 
responses using a multimodal measurement preparation. Psilocin (2 mg/kg or 0.03 mg/kg i.v.) or 
vehicle was administered to rats (N = 6/group) during either phMRI scanning or concurrent imaging 
of cortical blood flow and recording of local field potentials. Compared to vehicle controls psilocin (2 
mg/kg) evoked phMRI signal increases in a number of regions including olfactory and limbic areas 
and elements of the visual system. PhMRI signal decreases were seen in other regions including 
somatosensory and motor cortices. Investigation of neurovascular coupling revealed that whilst 
neuronal responses (local field potentials) to sensory stimuli were decreased in amplitude by psilocin 
administration, concurrently measured haemodynamic responses (cerebral blood flow) were 
enhanced. The present findings show that psilocin evoked region-specific changes in phMRI signals 
in the rat, confirming recent human data. However, the results also suggest that the haemodynamic 
signal changes underlying phMRI responses reflect changes in both neuronal activity and 
neurovascular coupling. This highlights the importance of understanding the neurovascular effects of 
pharmacological manipulations for interpreting haemodynamic neuroimaging data. 
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Abbreviations 
 
AUC - area under the curve 
BOLD - blood oxygen level dependent 
CBF - cerebral blood flow 
ISI - inter-stimulus-interval 
LC - locus coeruleus 
LFP - local field potential 
phMRI - pharmacological MRI 
ROI - region of interest 
SSRI - selective serotonin reuptake inhibitor 
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Introduction 
 
Pharmacological MRI (phMRI) offers the opportunity for in vivo characterisation of the neurophysiological effects 
of drugs on the brain. As such, it is becoming an increasingly important tool in basic research, drug discovery and 
development (Borsook et al., 2006; Murphy and Mackay, 2011; Wise and Tracey, 2006), and in research studies 
involving clinical populations (Fleisher et al., 2009; Mukherjee et al., 2014; Reynell and Harris, 2013). As it is a 
technique that can be deployed in both human and experimental animal research paradigms, phMRI is also 
finding an important translational role in neuropsychopharmacological research (Couch et al., 2013; Schwarz et 
al., 2007). This approach has recently been applied to psilocybin, the active constituent of “magic” mushrooms; 
which is of interest due to its potential utility in treating affective disorders (Carhart-Harris et al., 2012a, 2012b; 
Grob et al., 2011; Vollenweider and Kometer, 2010). 
Psilocybin, similar to other hallucinogenic agents, is an agonist at the serotonin 2A (5-HT2A) receptor, which is the 
primary mediator of its hallucinogenic effects (Quednow et al., 2012; Vollenweider et al., 1998) but whether and 
how this action is relevant to its therapeutic effects is unclear. It also shows affinity for all other serotonin 
receptors, with the exception of 5-HT3 (Halberstadt and Geyer, 2011). 5-HT2A receptor agonism is known to 
modulate pyramidal cell activity in the prefrontal cortex and anterior cingulate cortex, areas implicated in 
affective disorders (Vollenweider and Kometer, 2010). Positron emission tomography (PET) studies in humans 
show changes in cerebral glucose metabolism in the anterior cingulate cortex as well as in other frontal areas 
associated with cognitive changes following psilocybin administration (Gouzoulis-Mayfrank et al., 1999; 
Vollenweider et al., 1997) while widespread decreases in cerebral blood flow (CBF) and phMRI signals have been 
observed (Carhart-Harris et al., 2012a).  
Findings such as those described above are potentially important for guiding the development of therapeutic 
drugs, as well as for refining our understanding of brain disease. However, interpretation of phMRI data is not 
straightforward, as the haemodynamic changes upon which the imaging signals depend, such as the BOLD 
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response, are not a direct measure of neuronal activity, but rather rely on the relationship between 
haemodynamic changes and the underlying neuronal activity (Logothetis, 2008). In pharmacological 
neuroimaging, this relationship, known as neurovascular coupling, may be affected by both the pharmacological 
manipulations themselves and/or by resultant alterations in neurotransmission (Martin and Sibson, 2008). This 
means that phMRI studies cannot solely be interpreted in terms of the effects of the drug of interest upon 
neurons. 
In the case of psilocybin, whilst the pronounced phMRI signal decreases observed could be interpreted as 
evidence of neuronal deactivation (Carhart-Harris et al., 2012a), the physiological mechanisms producing 
decreased phMRI signals, and their relationship to neuronal activity remains unclear. Indeed, such processes may 
be highly dependent on differences between anatomical regions, and local synaptic input, as well as a number of 
factors (Kim and Ogawa, 2012; Lauritzen et al., 2012). 
In vivo, psilocybin undergoes first pass metabolism to psilocin, the active metabolite thought to account for most 
of the psychotropic effects of psilocybin administration (Hasler et al., 1997; Passie et al., 2002). A further potential 
confound in interpretation of BOLD signals in the case of psilocin is the combined neuronal and vascular effects of 
serotonergic drugs (Cohen et al., 1996; Fukuda et al., 2002). The 5-HT2A receptor has vasoconstrictive effects 
(Kovács et al., 2012; Martin, 1994), and psilocin also has affinity for the 5-HT1D and 5-HT1B receptors (Halberstadt 
and Geyer, 2011), which have both neuronal and vascular effects (Gupta and Villalón, 2010; Kovács et al., 2012). 
Additionally, serotonergic innervation of the cerebrovasculature may result in vascular effects of serotonin drugs 
that are separate from their direct actions on neuronal receptors (Hamel, 2006). 
In experimental animal models, it is possible to combine neuronal recordings with simultaneous measurement of 
haemodynamics in order to better characterise the source of the negative BOLD signal and investigate in fine 
detail the coupling between neuronal and haemodynamic signal changes (Boorman et al., 2010). Evidence 
suggests negative BOLD signals can have separable haemodynamic (Devor et al., 2005; Harel et al., 2002) and 
neuronal (Shmuel et al., 2006) sources and may occur in the presence of increased neuronal signalling 
(Angenstein et al., 2009). Furthermore, in cases where negative BOLD signals are associated with reduced 
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neuronal responses it is difficult in a phMRI paradigm to distinguish between direct drug effects and the effects of 
activation of inhibitory interneurons (Shih et al., 2009). In summary, a more detailed understanding of 
haemodynamic-based neuroimaging signals in the context of pharmacological manipulations is important for the 
continued application of phMRI techniques in human subjects. 
The aim of this study was to determine the effects of pharmacological manipulation of serotonergic 
neurotransmission by psilocin on the relationship between neuronal activity and the haemodynamic responses 
that underpin neuroimaging signal changes. We used a rodent model in which we combined whole brain phMRI 
measures of drug action with determination of neurovascular coupling relationships by concurrent measurement 
of neuronal activity and cerebral blood flow changes in response to sensory stimulation. 
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Materials and methods 
Animals and Experimental Design 
Male Sprague-Dawley rats (Charles River, UK) weighing 213-381g were used. Animals were housed under a 12:12 
hour light/dark cycle, with food and water available ad libitum. All experiments were carried out in accordance 
with the UK Animals (Scientific Procedures) Act (1986) under a U.K. Home Office licence. 18 Animals were used 
for phMRI data acquisition, comprising vehicle control, low-dose and high-dose groups (N=6 per group). A further 
12 animals were used for concurrent cerebral blood flow and neuronal activity measures, comprising drug and 
vehicle control groups (N=6 per group) in a repeated measures design (pre and post-drug stimulation and data 
acquisition epochs). 
 
Surgical procedures 
Animals were anaesthetised with 4-5% isoflurane in a 30:70 mixture of oxygen and nitrogen, and maintained on 
2–3% isoflurane for the duration of surgical procedures. Animals were tracheotomised and the femoral vein and 
artery cannulated. To record cerebral blood flow, high resolution laser speckle contrast imaging was conducted. 
The animal’s head was fixed in a stereotaxic frame and a window in the cranium was thinned over the left 
somatosensory cortex. To record neuronal activity, a burr hole was drilled in the rostrolateral corner of the 
thinned cranial window and a recording electrode was inserted to a depth of 0.5mm. Following surgery, animals 
were maintained on 1.5% isoflurane anaesthesia for the remainder of the experiment. At the end of all 
experiments, animals were killed by overdose with pentobarbital or transcardially perfused under terminal 
anaesthesia. 
 
Drugs 
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Psilocin (Lipomed, Arlesheim, Switzerland and Tocris, Abingdon, UK) was dissolved in 0.05mM tartaric acid vehicle 
and 1N sodium hydroxide used to raise the pH to 5-7. Final concentrations were 1mg/mL, for injections at a dose 
of 2mg/kg, and 0.075mg/mL for injections at a dose of 0.03mg/kg. 
 
Functional MRI experiments 
Functional MRI acquisitions were carried out on a 9.4T horizontal bore MRI system (Agilent Technologies, UK) 
using a 72mm volume coil (InsightMRI, Worcester MA, USA; m2m Imaging, Cleveland OH, USA and RAPID 
Biomedical, Rimpar, Germany). Datasets of 26 horizontal slices to cover the whole brain were acquired using a 
T2*-weighted multi-echo gradient-echo sequence with the following parameters: flip angle = 15°; matrix size = 96 
X 96; relaxation time (TR) = 625ms; echo time (TE) = 3–18ms (6 echos, 3ms apart); slice thickness=0.5mm. One 
volume was acquired each minute. Baseline datasets (15 min) were acquired before i.v. administration of psilocin 
(2mg/kg or 0.03mg/kg) or vehicle (N=6/group), and imaging continued for 45 minutes after drug administration. 
Arterial blood gases were sampled before and after imaging.  
 
Cerebral blood flow and neuronal activity measurements 
The laser speckle contrast imager (FLPI-2, Moor Instruments, Axminster, UK; 785nm laser diode; 576x768 pixel 
greyscale CCD image capture) was positioned above the thinned cranial window and blood flow was imaged at 
25Hz and recorded using moorFLPI Measurement v3.0 (Moor Instruments, UK). Local field potentials (LFPs) were 
simultaneously acquired from the implanted electrode (0.155mm diameter, Teflon insulated platinum; Bilaney 
Consultants Ltd., Sevenoaks, UK), sampled at 10kHz using an isolated amplifier unit coupled to a data acquisition 
device (systems 1902 and 1401, Cambridge Electronic Design, Cambridge, UK), and recorded using a PC running 
Spike2 software (Cambridge Electronic Design, UK), which also controlled stimulus delivery. There was a minimum 
45 minute delay before the start of recordings to avoid the influence of cortical spreading depression effects 
following electrode implantation. 
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Stimulation Protocol 
Prior to administration of 2mg/kg psilocin or vehicle (N=6/group) animals underwent 10 whisker pad stimulation 
trains of 16s duration, with a 60s inter-stimulus-interval (ISI), at a frequency of 10Hz. Following this, 60 
stimulation trains of 2s duration, with a 25s ISI, at frequencies of 1, 2, 5, 10, 20 and 40 Hz were carried out. The 
order of stimulus frequencies was pseudorandomised. In all cases the amplitude of the stimulus was 1.2mA and 
the stimulation pulse width was 0.3ms. Subsequently, four 30s duration episodes of hypercapnia (10% CO2) were 
induced, with an interval of 3 minutes between the start of each episode. After drug administration the 
stimulation and hypercapnia paradigms were repeated as before. 
 
Data analysis 
fMRI data were averaged across echoes prior to analysis in order to increase the contrast-to-noise ratio. Data 
were analysed using FEAT (FMRI Expert Analysis Tool) Version 5.92, part of FMRIB's Software Library (FSL, 
www.fmrib.ox.ac.uk/fsl; 39). For analysis of individual animals, data were smoothed, the time of drug 
administration used as a regressor in the general linear model with the scan registered to a standard template 
(Schweinhardt et al., 2003). Activated voxels were identified using a cluster thresholding method (Worsley et al., 
1992) with a z-score threshold of 2.3 and cluster significance level of 0.05. Individual animal analyses were 
combined for higher level analysis using a fixed effects model to compare the effects of the two doses of psilocin 
to placebo, and to generate mean change in BOLD activation for each group. Regions of interest (ROIs) for time 
series extraction were defined as areas showing significant BOLD signal change in animals that received 2mg/kg 
psilocin within the following anatomical ROIs based on the changes in human subjects seen in (Carhart-Harris et 
al., 2012a); the hypothalamus, amygdala and cingulate cortex. The somatosensory cortex was also included. 
Extracted time series were normalised to the baseline 15 minutes of pre drug administration scanning and 
averaged in 5 minute bins.  
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Processing of laser speckle and LFP data was carried out using custom-written code in Matlab (2013a), and SPSS 
21 was used for statistical analysis. Laser speckle data were downsampled to 5Hz. For CBF value changes in 
response to whisker stimulation, statistical parametric mapping was used to identify a responsive ROI. Time series 
data from this region were extracted and normalised to a 10s baseline period preceding each stimulation train to 
give percentage changes in cerebral blood flow. The area under the curve (AUC) and maximum for each response 
were calculated. Where stimulation trains were of 16s duration, both early (0-8s after stimulation onset) and late 
(10-20s after stimulation onset) response maxima were identified. The response maxima for each animal (pre- 
and post-drug treatment) were divided by the pre-drug maxima to give a measure of fractional change in 
response magnitude. Statistical comparisons were made using multifactorial ANOVA where pre- and post-drug 
administration, drug type and stimulation frequency (where applicable) were used as factors. 
 
For analysis of data from hypercapnic challenge, the entire thinned skull area was used as an ROI and the 
extracted CBF data were normalised to a 25s baseline prior to the onset of each CO2 challenge. Data were 
normalised as for whisker stimulation experiments and smoothed using a Savitsky-Golay filter. Statistical 
comparisons were by two-way ANOVA, where pre- and post-drug administration and drug type were used as 
factors and a p value of less than 0.05 was considered significant. 
 
In electrophysiological recordings the stimulation artefact was removed from the LFP response to each pulse in 
each stimulation episode. The stimulation artefact was replaced by a straight line vector containing the same 
number of points as the stimulation afterfact and connecting the last point before and the first point after the 
artefact. The baseline of the response to each stimulation train was set to zero by subtracting the mean 
calculated over 100ms prior to stimulation onset. Data were band-pass filtered (pass between 17.36Hz and 
2604.25Hz) to remove low and high frequency noise. To quantify neuronal response magnitudes, the AUC was 
calculated for each pulse in the stimulation train (over a 20.5ms period following stimulation onset) and values 
were summed over the stimulation train. Statistical comparisons were made as for the CBF responses to 
stimulation. 
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One animal in the vehicle-treated group was excluded from these analyses as it showed a maximal CBF response 
to stimulation before drug administration that was more than eleven standard deviations greater than the mean 
maximum response seen in other animals in the group. 
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Results 
Functional MRI 
Psilocin, at a dose of 2mg/kg, produced a mixed pattern of positive and negative BOLD signal changes throughout 
the brain compared to vehicle treated controls. A summary of the regions showing signal changes is presented in 
Table 1. At a dose of 0.03mg/kg psilocin produced a small BOLD signal decrease in the cerebellum compared to 
vehicle treated controls but had no effect in other regions. Consequently, experiments carrying out concurrent 
measurement of neuronal activity and CBF changes used psilocin at a dose of 2mg/kg for pharmacological 
manipulation. 
Time series extracted from regions showing significant BOLD signal changes demonstrated decreases in BOLD 
signal in the cingulate cortex and somatosensory cortex after drug administration in animals receiving 2mg/kg 
psilocin (Figure 1A & C; 2A, E, D & H), but an increased BOLD signal in the hypothalamus and amygdala (Figure 1B; 
2B, F, C & G). Whole brain activation maps for animals that received psilocin at a dose of 2mg/kg are shown in 
Supplementary Figures 1 and 2. A NIFTI format raw brain image from a representative animal in the vehicle 
control group is also provided in the supplementary materials for this paper. 
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Increased BOLD signal vs vehicle Decreased BOLD signal vs vehicle 
Olfactory and limbic areas Prelimbic cortex 
 Amygdalar nuclei Cingulate cortex 
 Olfactory tubercle Primary motor cortex 
 Piriform cortex Secondary motor cortex 
 Endopiriform nucleus Somatosensory cortex 
Substantia nigra, pars reticulata  Barrel cortex 
Optic tract Thalamic nuclei 
Hypothalamic nuclei  Dorsal lateral geniculate nucleus 
Hippocampus  lateral posterior thalamic nucleus 
 Dentate gyrus Dorsolateral periaqueductal grey 
 Subiculum Superior colliculus 
 Presubiculum Entorhinal cortex 
Cerebral peduncle Hippocampus 
Pontine nuclei  CA3 
 Gigantocellular reticular nucleus  CA1 
 Paramedian reticular nucleus  Fimbria 
 Lateral and medial habenulae 
 Visual cortex 
 
Table 1: Anatomical regions showing BOLD signal changes following administration of 2mg/kg psilocin. 
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Figure 1: At a dose of 2 mg/kg psilocin produced BOLD signal decreases in the cingulate cortex compared to 
vehicle treated controls while a dose of 0.03 mg/kg produced no change (A). Signal decreases were also observed 
at a dose of 2 mg/kg in the somatosensory cortex (C). The same dose produced signal increases in the amygdala 
and hypothalamus while a dose of 0.03 mg/kg produced no change in the same regions (B). All experimental 
groups have N=6.  
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Figure 2: Changes in BOLD signal magnitude in brain regions identified in Figure 1. (A-D) Time series changes in 
the four brain regions showing BOLD activation/deactivation. Dotted lines represent raw traces from individual 
animals that received a 2mg/kg dose of psilocin, solid line is the mean of these animals. Blue and red lines 
represent the mean signal changes from animals that received vehicle or 0.03mg/kg psilocin, respectively, for 
comparison. The average traces for these groups have been low pass filtered to improve clarity. (E-H) Percentage 
change in BOLD signal magnitude relative to baseline for each of the four identified brain regions. The signal 
magnitude was calculated by averaging over the period from 20-35 minutes after administration of 2mg/kg 
psilocin (amygdala, cingulate cortex and somatosensory cortex) or 5-20 minutes after drug administration 
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(hypothalamus). Error bars represent standard error of the mean. MANOVA performed on the signal magnitude 
values (as summarised in E-H) revealed a significant effect of drug dose (Hotelling’s Trace: df=8, 22; F=2.424; 
p=0.048).  
 
Haemodynamic responses to somatosensory stimulation 
Psilocin treated animals showed increased haemodynamic response amplitude to whisker stimulation following 
drug administration (Figure 3A). There was a significant effect of drug treatment on the amplitude of the initial (0 
– 8s from stimulation onset) part of the CBF response to long, 16s duration, 10Hz stimulation and a significant 
interaction between this effect and pre-/post-drug administration. There was a significant effect of pre-/post-drug 
administration on this measure (statistics summarised in Table 2). There were no significant effects on the 
maximum of the second part of the response (10–20s from stimulation onset; statistics summarised in Table 2). 
Parameter Factor df F p 
Maximum of first phase (0 – 8s  Drug treatment 1,9 5.338 0.046* 
from stimulation onset) of CBF response Pre/post drug administration 1,9 6.632 0.030* 
to 10Hz, 16s duration stimulation 
Drug treatment x Pre/post drug 
administration interaction 
1,9 6.187 0.035* 
     
Maximum of second phase (10 – 20s  Drug treatment 1,9 0.033 0.861 
from stimulation onset) of CBF response Pre/post drug administration 1,9 0.137 0.720 
to 10Hz, 16s duration stimulation 
Drug treatment x Pre/post drug 
administration interaction 
1,9 2.037 0.187 
     
Time to half maximum CBF response to Drug treatment 1,9 0.198 0.667 
10Hz, 16s duration stimulation Pre/post drug administration 1,9 0.031 0.863 
 
Drug treatment x Pre/post drug 
administration interaction 
1,9 0.131 0.726 
Table 2: Summary of statistical analyses of haemodynamic responses to 10Hz, 16s duration stimulation. * = p < 
0.05. 
 
Maximum CBF responses to mixed frequency (1-40Hz) whisker stimulations of short, 2s duration did not differ 
according to drug treatment or pre-/post-drug administration and no significant effect of whisker stimulation 
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frequency on response maxima was found (Figure 3C, statistics summarised in Table 3). In order to investigate 
whether the effects observed with a longer (16s duration) stimulation (see above) were replicated for this specific 
frequency (10Hz) in the short stimulation condition, a separate two-way ANOVA was run using only data for the 
2s, 10Hz stimuli. This showed a significant effect of drug treatment and a significant interaction effect of drug 
treatment with pre-/post-drug administration on maximum CBF response to whisker stimulation (Table 3, bottom 
row). Specifically, psilocin treated animals showed a greater maximum CBF response after receiving drug 
treatment (Figure 3C) in agreement with the data from the 16s stimulation condition. Results of equivalent 
analyses for the other five stimulation frequencies and statistics are shown in Supplementary Table S1. 
 
Parameter Factor df F p 
Maximum CBF response to mixed  Drug treatment 1,9 2.787 0.129 
frequency, 2s duration stimulation Pre/post drug administration 1,9 0.524 0.488 
 
Drug treatment x Pre/post drug 
administration interaction 
1,9 3.110 0.112 
 Stimulation frequency 5,45 1.207 0.321 
 
Stimulation frequency x drug treatment 
interaction 
5,45 2.115 0.081 
 
Pre/post drug administration x frequency 
interaction 
5,45 1.965 1.02 
 
Pre/post drug administration x frequency 
x drug treatment interaction 
5,45 1.866 0.119 
     
Time to half maximum CBF response to  Drug treatment 1,9 1.314 0.281 
mixed frequency, 2s duration Pre/post drug administration 1,9 1.029 0.337 
stimulation 
Drug treatment x Pre/post drug 
administration interaction 
1,9 1.200 0.302 
 Stimulation frequency 5,45 1.176 0.336 
 
Stimulation frequency x drug treatment 
interaction 
5,45 0.723 0.610 
 
Pre/post drug administration x frequency 
interaction 
5,45 1.498 0.209 
 
Pre/post drug administration x frequency 
x drug treatment interaction 
5,45 1.800 0.132 
Analysis of 10Hz CBF response data only Drug treatment 1,9 5.462 0.044* 
 Pre/post drug administration 1,9 3.359 0.100 
 
Drug treatment x Pre/post drug 
administration interaction 
1,9 5.125 0.050* 
Table 3: Summary of statistical analyses of haemodynamic responses to mixed frequency, 2s duration stimulation. 
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No effects of drug treatment were evident on the latency of the haemodynamic responses to either long, 16s 
duration, or short mixed-frequency whisker stimulation (statistics shown in Table 2). There were no significant 
differences between the maximal CBF responses of vehicle and psilocin treated animals to 30s of hypercapnia 
(statistics shown in Table 4). 
 
Parameter  Factor 
Maximum CBF response to 30s   Drug treatment 
increased CO2 concentration  Pre/post drug administration 
 
 Drug treatment x Pre/post drug 
administration interaction 
Table 4: Summary of statistical analyses of haemodynamic responses to 30s increased CO2 concentration. 
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Figure 3: Treatment with 2 mg/kg psilocin increases the magnitude of the haemodynamic response to whisker 
stimulation in the somatosensory cortex. In a long stimulation paradigm this was evident in the initial phase of the 
response where animals that received psilocin had an increased response amplitude (A). The magnitude of the 
neuronal response in the somatosensory cortex to the same stimulation paradigm was unaltered (B). When 
shorter stimulations with multiple frequencies were applied this effect was significant only at 10 Hz (1C). 
Neuronal response magnitude was decreased after psilocin administration at high stimulation frequencies in the 
short stimulation, mixed frequency paradigm (D). Data are mean ± SEM, N=6 for psilocin treatment, N=5 for 
vehicle treatment. 
Neuronal responses to somatosensory stimulation 
Neuronal responses in the long, 16s whisker stimulation condition, as determined by the AUC of LFP responses, 
were not significantly altered by drug treatment condition (see Figures 3B and 4; statistics summarised in Table 
5). 
In contrast, in the short, mixed frequency stimulation condition, psilocin treated animals showed a significant 
reduction in neuronal response magnitude (Figure 3D). The drug type x pre-/post-drug administration x 
stimulation frequency interaction effect was significant. There was also a significant interaction between drug 
type and pre-/post-drug administration as well as an effect of drug type. There were also significant effects of 
pre-/post-drug administration, stimulation frequency and a significant interaction between these effects. Post-hoc 
a two-way ANOVA was carried out on each stimulation frequency to determine whether the effects of psilocin 
administration were observed at specific frequencies. The Bonferroni technique was used to adjust the α level for 
multiple comparisons (i.e. p<0.0083 was considered significant). A significant drug type x pre-/post-drug 
administration effect was found at all frequencies with psilocin treated animals showing a decrease in AUC of the 
LFP response after drug administration. This effect was most pronounced at 20 and 40Hz stimulation frequencies 
(Figure 3D; statistics summarised in Table 6). 
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Stimulation frequency Factor df F p 
10Hz, 16s stimulation Drug treatment 1,9 0.117 0.740 
 Pre/post drug administration 1,9 0.136 0.721 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 0.172 0.688 
Table 5: Summary of statistical analyses of neuronal response magnitudes to 10Hz, 16s duration stimulation. 
 
 
 
Figure 4: Average neuronal responses to long, 16s duration, 10Hz whisker stimulation were not significantly 
altered by administration of psilocin. Black lines show response means, coloured bands represent SEM, N=6 for 
psilocin treatment, N=5 for vehicle treatment. (A) The average response to the first pulse in the stimulation train. 
(B) The average response to all subsequent pulses in the train. 
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Stimulation 
frequency 
Factor df F p 
Mixed frequency, 2s Drug treatment 1,9 30.539 <0.001* 
stimulation Pre/post drug administration 1,9 48.122 <0.001* 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 111.839 <0.001* 
 Stimulation frequency 1,9 3631.889 <0.001* 
 Stimulation frequency x drug treatment interaction 5,45 50.504 <0.001* 
 Pre/post drug administration x frequency interaction 5,45 21.432 <0.001* 
 
Pre/post drug administration x frequency x drug 
treatment interaction 
5,45 136.091 <0.001* 
     
1Hz Drug treatment 1,9 2.009 0.187 
 Pre/post drug administration 1,9 15.051 0.003* 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 44.132 <0.001* 
     
2Hz Drug treatment 1,9 1.983 0.189 
 Pre/post drug administration 1,9 80.495 <0.001* 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 39.832 
<0.001* 
     
5Hz Drug treatment 1,9 2.556 0.141 
 Pre/post drug administration 1,9 157.101 <0.001* 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 14.051 0.004* 
     
10Hz Drug treatment 1,9 0.458 0.514 
 Pre/post drug administration 1,9 256.354 <0.001* 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 33.898 
<0.001* 
     
20Hz Drug treatment 1,9 37.478 <0.001* 
 Pre/post drug administration 1,9 3.610 0.087 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 88.602 <0.001* 
     
40Hz Drug treatment 1,9 69.494 <0.001* 
 Pre/post drug administration 1,9 29.415 <0.001* 
 
Drug treatment x Pre/post drug administration 
interaction 
1,9 192.861 <0.001* 
Table 6: Summary of statistical analyses of neuronal response magnitudes to mixed frequency, 2s  duration 
stimulation. * = p < 0.0083. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
21 
 
Discussion 
We have demonstrated that the BOLD signal changes observed in response to psilocin administration are 
associated with alterations in neurovascular coupling. Psilocin produced BOLD signal changes in anatomically 
distinct regions including olfactory and limbic systems, visual system, hippocampus, hypothalamus, prelimbic, 
cingulate and somatosensory cortices at a dose of 2mg/kg. BOLD signal changes did not occur in the same 
direction throughout the brain, with signal increases and decreases observed in different regions. Detailed 
investigation of CBF and neuronal responses to whisker stimulation in the somatosensory cortex, a region of 
psilocin-mediated decreased phMRI signal, demonstrated stimulation frequency specific augmentation of the CBF 
response by psilocin, accompanied by decreased neuronal response magnitudes; indicating modulation of the 
relationship between neuronal activity and CBF. These findings suggest that psilocin alters neurovascular coupling 
and that caution is required when making inferences about drug effects on neuronal activity from changes 
detected in neuroimaging signals. 
 
The opposing directionality of LFP and CBF response changes in the somatosensory cortex due to psilocin suggest 
altered neurovascular coupling is partly responsible for the observed BOLD-phMRI changes. The unaltered CBF 
responses to hypercapnia challenge indicate that vascular reactivity was unaffected by administration of psilocin 
(Rostrup et al., 1994). 5-HT2ARs are also expressed on both pyramidal cells (Willins et al., 1997) and inhibitory 
interneurons (Andrade, 2011; Puig and Gulledge, 2011) suggesting that agonism of this receptor can have both 
excitatory and inhibitory effects on downstream neuronal signalling. Cortical inhibitory interneurons are capable 
of producing both vasodilation and vasoconstriction (Cauli et al., 2004); providing a mechanism by which reduced 
synaptic activity may actually be associated with increased CBF. The linearity of the neurovascular response to 
whisker stimulation has also been proposed to be dependent on changes in the background balance of inhibition 
and excitation in the brain (Buzsáki et al., 2007; Lauritzen et al., 2012), providing additional means by which 
neurovascular coupling may be altered by psilocin. The role of extra-cortical effects of psilocin on other receptor 
subtypes in modulating the somatosensory response to stimulation cannot be ruled out. For instance, the locus 
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coeruleus (LC) modulates CBF responses to whisker stimulation (Toussay et al., 2013) and LC activity is known to 
be inhibited by 2,5-dimethoxy-4-iodoamphetamine (DOI), another non-selective 5-HT2AR agonist (Szabo and Blier, 
2001). In addition, Figure 3 shows that neuronal response to whisker stimulation at 40Hz increased over time in 
vehicle-treated controls. The directionality of this effect is opposite to that found in the psilocin group. We are 
unsure as to why this occurred, but it could be due to an effect of anaesthetic depth varying over time or the 
effects of the vehicle; tartaric acid. Since the change is in the opposite direction to that induced by psilocin, it is 
possible that the changes we observed in the psilocin group are being partially masked by this effect. 
Recent work by Riga et al. (2014) investigated the neuronal and fMRI signal effects of the 5-HT2AR agonist and 
hallucinogen 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also in rats. In agreement with the present 
findings they report a mixed pattern of positive and negative BOLD signal changes in the brain, with widespread 
areas of decreased BOLD signal occurring in sensory cortex and subcortical BOLD signal increases (e.g. in 
hippocampus).  Riga et al. also showed reduced low frequency (0.15-4Hz) oscillations and increased pyramidal 
spiking activity associated with decreased BOLD signal in medial prefrontal cortex following 5-MeO-DMT 
administration. Against a background of reduced neuronal oscillatory power in this ‘delta’ range, haemodynamic 
response signals have been shown elsewhere to increase (Niessing et al., 2005), providing an additional 
explanation for the enhancement of stimulus-evoked haemodynamic responses observed here following psilocin 
treatment.  
 
Psilocin has both on- and off-target actions that may be important for the interpretation of the results reported 
here. Although there is strong evidence that the hallucinogenic effects of psilocin are associated with 5-HT 2A 
activation (Quednow et al., 2012; Halberstadt, 2015), the indirect nature of using haemodynamic neuroimaging 
signals as proxy measures for neuronal activity make off-target effects, including non-hallucinogenic and 
peripheral actions mediated by other receptor subtypes, an important consideration. For example, psilocin has 
effects at most 5-HT receptor subtypes and also some dopamine receptors (e.g. see Ray, 2010). In particular, the 
effects of psilocin on 5-HT 1B/1D receptors, which are expressed on cerebral vasculature, may have a direct ‘non-
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neuronal’ role in mediating haemodynamics. These off-target effects could contribute to the changes in neural-
haemodynamic coupling observed here, and would again limit the extent to which pharmacological neuroimaging 
readouts could be interpreted as indicating increases or decreases in neuronal activity. 
The findings presented here are particularly relevant to situations where alterations in brain responses to sensory 
(e.g. visual, auditory) stimulation are being investigated using neuroimaging, as they demonstrate that 
serotonergic manipulations may alter the relationship of BOLD signal changes to neuronal activity. To exemplify, 
in isolation, our haemodynamic (i.e. neuroimaging) data suggests that psilocin increases the magnitude of cortical 
responses to sensory stimulation (Figure 3A). In fact, our concurrent measurement of neuronal response 
magnitudes suggests that if anything, the opposite is true. Furthermore, these findings may have implications for 
neuroimaging studies in clinical cohorts where serotonergic anomalies are known to exist (Rive et al., 2013). 
Alterations of BOLD responses to stimulation in conjunction with pharmacological serotonin manipulations, such 
as with selective serotonin reuptake inhibitors (SSRIs), have been documented in human subjects (Klomp et al., 
2013; Rive et al., 2013; Windischberger et al., 2010) and our findings, based on concurrent measurement of 
neuronal and CBF changes underlying BOLD signals, demonstrate why caution should be exercised in the 
interpretation of such findings. Specifically, many interpretations of BOLD-fMRI signal changes assume a 
monotonic relationship between evoked neuronal and haemodynamic response magnitudes, something we have 
here demonstrated to be altered by psilocin administration. Furthermore, the alteration in neurovascular 
coupling we report here might explain, in part, the apparent discrepancy between fMRI and PET findings of 
decreased CBF (Carhart-Harris et al., 2012a) and increased glucose metabolism (Gouzoulis-Mayfrank et al., 1999; 
Vollenweider et al., 1997) in human studies with psilocybin and related drugs. Although it is widely assumed that 
neuronal activity, glucose metabolism, cerebral blood flow and fMRI BOLD signals increase (or decrease) in 
tandem, this assumption has only been extensively tested in conditions of sensory stimulus-induced activation 
change (and where caveats have been found): physiological investigations in preclinical models will continue to be 
important for detailing these relationships in pharmacological neuroimaging contexts. 
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We have shown that the anatomical areas affected by psilocin in the rat are congruent with those affected in the 
human brain (Carhart-Harris et al., 2012a). The direction of our observed changes in the rat is not, however, 
entirely consistent with those observed in humans. In humans, BOLD signals were uniformly decreased in 
response to psilocin administration, while BOLD signals in rat were observed to increase as well as decrease, 
depending on the anatomical location. The divergence in direction of signal change may reflect either an 
interspecies difference in the effects of the drug or the larger effective dose used in our study compared to that 
of Carhart-Harris and colleagues (Carhart-Harris et al., 2012a) (2 mg/kg vs. 2 mg/total body weight, respectively). 
The absence of changes observed at 0.03mg/kg in our study may be attributable to interspecies differences 
between rats and humans. The dose of 0.03mg/kg was calculated to be equivalent to the dose used by Carhart-
Harris and colleagues (2mg/subject in their study divided by our assumed 70kg bodyweight per subject). Without 
scaling for interspecies pharmacokinetic differences; however, there may not be direct concordance between the 
two doses (Boxenbaum, 1982; Lin, 1998). 
 
Another important difference between our work and previous human studies is the use of anaesthesia. Although 
methods to acquire neuronal and haemodynamic data in awake animals have been developed in our laboratory 
and elsewhere (C. Martin et al., 2013; C. J. Martin et al., 2013; Takuwa et al., 2009), anaesthesia remains 
important to enable invasive and concurrent measurement of neuronal and haemodynamic data, especially in the 
context of drug treatments well-known for eliciting head-twitch responses (Corne and Pickering, 1967). 
Anaesthetics, including isoflurane as used in this study (the most popular choice for preclinical phMRI research 
(Haensel et al., 2015)), are known modulators of haemodynamic responses (Austin et al., 2005; Martin et al., 
2006; Tsurugizawa et al., 2010). Our experimental design, which included within-subjects measurement of the 
effects of psilocin, will, to some extent mitigate against this as a confounding factor as animal anaesthesia levels 
were constant throughout the pre- and post-drug conditions. The observation of CBF responses to stimulation 
under anaesthesia even in vehicle treated control animals as well as prior to drug administration also suggests 
that this effect did not obscure CBF responses in this study. This is consistent with data from previous work 
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(Franceschini et al., 2010; Masamoto et al., 2009; Sicard and Duong, 2005), which shows that under isoflurane 
anaesthesia, capacity for blood flow changes in response to neuronal activation remains. The effects of isoflurane 
on neurovascular coupling have also been demonstrated to be comparable to those of other anaesthetics 
(Franceschini et al., 2010). As a result we are confident that the effects of isoflurane on the results obtained in 
this study are small and were further minimised by using the lowest necessary dose of isoflurane for anaesthesia 
during experimental manipulations. Isoflurane is also known to have a variety of neuronal effects (Haensel et al., 
2015), among these, it is known to increase permeability of GABAA receptors to chloride. This effect could be 
relevant to the current study given the location of 5-HT2ARs on GABAergic neurons, however we did not find 
psilocin related alterations in the neuronal responses to whisker stimulation suggesting that any such effects were 
minimal. It has been suggested that the sedative dexmedetomidine could provide an alternate, ‘compromise’ 
means of avoiding the challenges of both general anaesthesia and awake rodent studies (Weber et al., 2006). 
However, recent research has demonstrated this drug to have a range of vascular, neuronal and neurovascular 
actions (Fukuda et al., 2013) and as such was judged to be less suitable for the present study. 
 
In conclusion, psilocin induced alterations in neurovascular coupling have implications for the interpretation of 
BOLD-phMRI based investigation of psilocin, and possibly other 5-HT agonists, as well as underlining the general 
need for caution in interpreting fMRI studies in the context of neuropharmacological manipulations (Shih et al., 
2009). Determining a plausible mechanism of action for this effect is necessary to progress research using such 
drugs. phMRI studies in human subjects are important in this endeavour, but additional studies will be necessary 
to connect the haemodynamic readouts provided by such non-invasive neuroimaging methods to better validated 
makers of neuronal activity, such as those provided by experimental animal studies. More generally, we suggest 
that such research is increasingly needed to underpin interpretation of non-invasive (haemodynamic) functional 
imaging studies of drug action in the human brain.   
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Supplementary information 
 
Figure S1: Whole brain maps showing BOLD signal increases in animals which received a 2mg/kg dose of psilocin 
compared to vehicle controls. 
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Figure S2: Whole brain maps showing BOLD signal decreases in animals which received a 2mg/kg dose of psilocin 
compared to vehicle controls. 
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Stimulation 
frequency 
Factor df F p 
1Hz Drug treatment 1,9 0.013 0.913 
 Pre/post drug administration 1,9 0.041 0.843 
 Drug treatment x Pre/post drug administration interaction 1,9 0.004 0.952 
     
2Hz Drug treatment 1,9 0.256 0.625 
 Pre/post drug administration 1,9 0.009 0.926 
 Drug treatment x Pre/post drug administration interaction 1,9 0.674 0.433 
     
5Hz Drug treatment 1,9 1.114 0.319 
 Pre/post drug administration 1,9 1.203 0.301 
 Drug treatment x Pre/post drug administration interaction 1,9 1.327 0.279 
     
10Hz Drug treatment 1,9 5.462 0.044* 
 Pre/post drug administration 1,9 3.359 0.100 
 Drug treatment x Pre/post drug administration interaction 1,9 5.125 0.050* 
     
20Hz Drug treatment 1,9 3.187 0.108 
 Pre/post drug administration 1,9 0.004 0.950 
 Drug treatment x Pre/post drug administration interaction 1,9 3.479 0.095 
     
40Hz Drug treatment 1,9 2.866 0.125 
 Pre/post drug administration 1,9 0.000 1.000 
 Drug treatment x Pre/post drug administration interaction 1,9 3.529 0.093 
Table S1: Frequency by frequency ANOVA results of comparisons of maximum CBF responses to 
stimulation. * = p < 0.05 
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• The pharmacological MRI (phMRI) response to psilocin is characterised in rats 
• Region specific increases and decreases  in phMRI signals are observed  
• Underlying neuronal and haemodynamic changes are also measured in vivo 
• Evidence for altered neuronal-haemodynamc (neurovascular) coupling by psilocin 
• phMRI interpretation should consider neurovascular as well as neuronal drug effects 
